Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venetoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 known ✓ | P10415 | 20/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | BAD | Q92934 | 1/20 | 1.00 |
| ▸ | NSD1 | Q96L73 | 1/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venetoclax SCHEMBL29801595 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29353714 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29360081 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL523816 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278845 | 0.99 | BCL2 (0.99) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278892 | 0.99 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278891 | 0.99 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038769 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038376 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699816 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262113-A1 | COMBINATION THERAPY USING MALT1 AND BCL-2 INHIBITORS AND METHODS OF REDUCING REGULATORY T CELLS | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-26 | — | — | WO | claimed |
| US-20250161351-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-22 | — | — | US | claimed |
| EP-4536250-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum (DE) | 2025-04-16 | — | — | EP | claimed |
| WO-2024027694-A9 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2025-01-02 | — | — | WO | claimed |
| EP-4384171-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2024027694-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2024-02-08 | — | — | WO | claimed |
| WO-2023237710-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-12-14 | — | — | WO | claimed |
| WO-2023016995-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | claimed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | claimed |
| CN-115505029-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-122094980-A | Bispecific antibody fusion molecules targeting CD180 and CD3 and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026105876-A1 | M1 MICROGLIA-TARGETING FUSION PEPTIDE AND USE THEREOF | 国立大学法人滋賀医科大学 | 2026-05-21 | — | — | WO | disclosed |
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12631645-B2 | Detection of BCL-2 family heterodimer complexes and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| CN-114044776-A | Salts of compounds and crystalline forms thereof | 和记黄埔医药（苏州）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20220040153-A1 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| CN-109462980-B | Combination of LSD1 inhibitors for the treatment of hematologic malignancies | 奥莱松基因组股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | BCL2 2297/4885BCL2L1 918/4885MCL1 61/4885 |
| US-12631645-B2 | Detection of BCL-2 family heterodimer complexes and use thereof | BCL2L10, BCL2L1, BCL2L2 | BCL2 4/4885BCL2L1 2/4885MCL1 7/4885 |
| US-20220040153-A1 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES | CD79B, CD99, BCL6 | BCL2 462/4885BCL2L1 513/4885MCL1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.